Cargando…

Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke

BACKGROUND: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhasin, Ashu, Srivastava, M.V. Padma, Mohanty, Sujata, Vivekanandhan, Sivasubramaniam, Sharma, Sakshi, Kumaran, Senthil, Bhatia, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123023/
https://www.ncbi.nlm.nih.gov/pubmed/27846623
http://dx.doi.org/10.1159/000446404
_version_ 1782469673961390080
author Bhasin, Ashu
Srivastava, M.V. Padma
Mohanty, Sujata
Vivekanandhan, Sivasubramaniam
Sharma, Sakshi
Kumaran, Senthil
Bhatia, Rohit
author_facet Bhasin, Ashu
Srivastava, M.V. Padma
Mohanty, Sujata
Vivekanandhan, Sivasubramaniam
Sharma, Sakshi
Kumaran, Senthil
Bhatia, Rohit
author_sort Bhasin, Ashu
collection PubMed
description BACKGROUND: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim report evaluates the safety, feasibility and efficacy (if any) of bone marrow-derived mononuclear stem cells (BM-MNC) in chronic ischemic stroke by studying the release of serum vascular endothelial growth factor (VEGF) and brain-derived neurotrophic growth factor (BDNF). METHODS: Twenty stroke patients and 20 age-matched healthy controls were recruited with the following inclusion criteria: 3 months to 1.5 years from the index event, Medical Research Council (MRC) grade of hand muscles of at least 2, Brunnstrom stage 2-5, conscious, and comprehendible. They were randomized to one group receiving autologous BM-MNC (mean 60-70 million) and to another group receiving saline infusion (placebo). All patients were administered a neuromotor rehabilitation regime for 8 weeks. Clinical assessments [Fugl Meyer scale (FM), modified Barthel index (mBI), MRC grade, Ashworth tone scale] were carried out and serum VEGF and BDNF levels were assessed at baseline and at 8 weeks. RESULTS: No serious adverse events were observed during the study. There was no statistically significant clinical improvement between the groups (FM: 95% CI 15.2-5.35, p = 0.25; mBI: 95% CI 14.3-4.5, p = 0.31). VEGF and BDNF expression was found to be greater in group 1 compared to group 2 (VEGF: 442.1 vs. 400.3 pg/ml, p = 0.67; BDNF: 21.3 vs. 19.5 ng/ml) without any statistically significant difference. CONCLUSION: Autologous mononuclear stem cell infusion is safe and tolerable by chronic ischemic stroke patients. The released growth factors (VEGF and BDNF) in the microenvironment could be due to the paracrine hypothesis of stem cell niche and neurorehabilitation regime.
format Online
Article
Text
id pubmed-5123023
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-51230232016-12-05 Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke Bhasin, Ashu Srivastava, M.V. Padma Mohanty, Sujata Vivekanandhan, Sivasubramaniam Sharma, Sakshi Kumaran, Senthil Bhatia, Rohit Cerebrovasc Dis Extra Original Paper BACKGROUND: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim report evaluates the safety, feasibility and efficacy (if any) of bone marrow-derived mononuclear stem cells (BM-MNC) in chronic ischemic stroke by studying the release of serum vascular endothelial growth factor (VEGF) and brain-derived neurotrophic growth factor (BDNF). METHODS: Twenty stroke patients and 20 age-matched healthy controls were recruited with the following inclusion criteria: 3 months to 1.5 years from the index event, Medical Research Council (MRC) grade of hand muscles of at least 2, Brunnstrom stage 2-5, conscious, and comprehendible. They were randomized to one group receiving autologous BM-MNC (mean 60-70 million) and to another group receiving saline infusion (placebo). All patients were administered a neuromotor rehabilitation regime for 8 weeks. Clinical assessments [Fugl Meyer scale (FM), modified Barthel index (mBI), MRC grade, Ashworth tone scale] were carried out and serum VEGF and BDNF levels were assessed at baseline and at 8 weeks. RESULTS: No serious adverse events were observed during the study. There was no statistically significant clinical improvement between the groups (FM: 95% CI 15.2-5.35, p = 0.25; mBI: 95% CI 14.3-4.5, p = 0.31). VEGF and BDNF expression was found to be greater in group 1 compared to group 2 (VEGF: 442.1 vs. 400.3 pg/ml, p = 0.67; BDNF: 21.3 vs. 19.5 ng/ml) without any statistically significant difference. CONCLUSION: Autologous mononuclear stem cell infusion is safe and tolerable by chronic ischemic stroke patients. The released growth factors (VEGF and BDNF) in the microenvironment could be due to the paracrine hypothesis of stem cell niche and neurorehabilitation regime. S. Karger AG 2016-10-19 /pmc/articles/PMC5123023/ /pubmed/27846623 http://dx.doi.org/10.1159/000446404 Text en Copyright © 2016 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission.
spellingShingle Original Paper
Bhasin, Ashu
Srivastava, M.V. Padma
Mohanty, Sujata
Vivekanandhan, Sivasubramaniam
Sharma, Sakshi
Kumaran, Senthil
Bhatia, Rohit
Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke
title Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke
title_full Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke
title_fullStr Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke
title_full_unstemmed Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke
title_short Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke
title_sort paracrine mechanisms of intravenous bone marrow-derived mononuclear stem cells in chronic ischemic stroke
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123023/
https://www.ncbi.nlm.nih.gov/pubmed/27846623
http://dx.doi.org/10.1159/000446404
work_keys_str_mv AT bhasinashu paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke
AT srivastavamvpadma paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke
AT mohantysujata paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke
AT vivekanandhansivasubramaniam paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke
AT sharmasakshi paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke
AT kumaransenthil paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke
AT bhatiarohit paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke